FI3513806T3 - Immunogeeninen koostumus - Google Patents
Immunogeeninen koostumus Download PDFInfo
- Publication number
- FI3513806T3 FI3513806T3 FIEP19159001.7T FI19159001T FI3513806T3 FI 3513806 T3 FI3513806 T3 FI 3513806T3 FI 19159001 T FI19159001 T FI 19159001T FI 3513806 T3 FI3513806 T3 FI 3513806T3
- Authority
- FI
- Finland
- Prior art keywords
- seq
- seo
- immunogenic composition
- fragment
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201221875 | 2012-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3513806T3 true FI3513806T3 (fi) | 2023-04-26 |
Family
ID=49724573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19159001.7T FI3513806T3 (fi) | 2012-12-05 | 2013-12-03 | Immunogeeninen koostumus |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9694064B2 (enExample) |
| EP (2) | EP2928489B1 (enExample) |
| JP (2) | JP6290918B2 (enExample) |
| CN (2) | CN104884081A (enExample) |
| AR (1) | AR093712A1 (enExample) |
| AU (1) | AU2013354186A1 (enExample) |
| BR (1) | BR112015012841B1 (enExample) |
| CA (1) | CA2893435C (enExample) |
| CY (1) | CY1121560T1 (enExample) |
| DK (2) | DK2928489T3 (enExample) |
| ES (2) | ES2721930T3 (enExample) |
| FI (1) | FI3513806T3 (enExample) |
| HR (2) | HRP20190711T1 (enExample) |
| HU (2) | HUE061273T2 (enExample) |
| LT (2) | LT3513806T (enExample) |
| PL (2) | PL3513806T3 (enExample) |
| PT (2) | PT3513806T (enExample) |
| SG (1) | SG11201503861UA (enExample) |
| SI (2) | SI3513806T1 (enExample) |
| TR (1) | TR201905272T4 (enExample) |
| WO (1) | WO2014086787A1 (enExample) |
| ZA (1) | ZA201503927B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045482T2 (hu) * | 2005-06-27 | 2019-12-30 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| EP2928489B1 (en) * | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| CN106659799B (zh) * | 2014-07-25 | 2020-07-17 | 碧奥辛斯有限责任公司 | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 |
| CA2976976C (en) | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CA3014498A1 (en) | 2016-03-21 | 2017-09-28 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN110691609B (zh) * | 2017-03-15 | 2024-04-19 | 诺瓦瓦克斯股份有限公司 | 用于诱导针对艰难梭菌的免疫应答的方法和组合物 |
| CN107397956A (zh) * | 2017-08-08 | 2017-11-28 | 南开大学 | 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用 |
| CN112512556A (zh) | 2018-01-16 | 2021-03-16 | 儿童医学中心公司 | 用于抑制wnt信号传导的组合物和方法 |
| GB201804092D0 (en) * | 2018-03-14 | 2018-04-25 | Imperial Innovations Ltd | Methods and compositions |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| CA3141165A1 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Vaccine compositions for clostridium difficile |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| AU2023393199A1 (en) * | 2022-12-13 | 2025-05-29 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| EP4658302A1 (en) | 2023-02-02 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| WO1988009797A1 (en) | 1987-06-05 | 1988-12-15 | The United States Of America, As Represented By Th | Autocrine motility factors in cancer diagnosis and management |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP2305303A3 (en) | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| EP1169456B1 (en) | 1999-04-09 | 2012-07-11 | Intercell USA, Inc. | Recombinant production of Clostridium difficile Toxin A or Toxin B |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| GB0525321D0 (en) * | 2005-12-13 | 2006-01-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| CA2664619C (en) * | 2006-10-12 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent |
| GB0711858D0 (en) | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
| AU2008299885C1 (en) | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| KR20110009157A (ko) | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| WO2010017383A1 (en) | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| US9290565B2 (en) * | 2011-05-27 | 2016-03-22 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| EP2928489B1 (en) * | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
-
2013
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 CA CA2893435A patent/CA2893435C/en active Active
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/en active
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
- 2013-12-03 DK DK19159001.7T patent/DK3513806T5/da active
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en not_active Ceased
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
-
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
-
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
-
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
-
2019
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230359T1 (hr) | Imunogeni pripravak | |
| Tatsi et al. | SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence | |
| Hotez et al. | Advancing a vaccine to prevent hookworm disease and anemia | |
| Qu et al. | Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| WO2008014979A3 (en) | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | |
| DK2280721T3 (da) | Indoleamin-2, 3-dioxygenasebaseret immunterapi | |
| JP2016502551A5 (enExample) | ||
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| TW201305192A (zh) | 新穎之組合物 | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| MX386620B (es) | Composicion de cannabis | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| NO20090062L (no) | Influensavaksine | |
| FI3564378T3 (fi) | Immunogeeninen koostumus | |
| MX2024013161A (es) | Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs) | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| Flach et al. | A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori | |
| MX2011003535A (es) | Composiciones de virus de herpes bovino-1, vacunas, y metodos. | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| Vitek et al. | Diphtheria Section 2: Licensed toxoid | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| Hu et al. | A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination | |
| JP2015529677A5 (enExample) |